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Background:evaluate the effectiveness of TachoSil® sponge 
on distal pancreatectomy remnant stump in reducing the rate 
and severity of post-operative pancreatic fistula (POPF) 
Methods:  
All consecutive patients requiring distal pancreatectomy were 
randomized in 45 centers. Principal endpoint: onset of “clinically 
relevant” POPF. Univariate and multivariate analyses searched 
for predictive factors.  
Results 
Of 270 patients randomized in 45 centers (134 with 
TachoSil®;136 without), 150/270(55.6%) sustained a POPF (74 
clinically relevant;76 clinically silent (27.4% and 28.1%, 
respectively): no statistically significant difference (NS) was 
found between patients with (41(30.6%) vs. 33(24.3%) without 
TachoSil®(p=0.276), or overall POPF (73(54.5%) with vs.
77(56.6%) without TachoSil®(p=0.807), but more clinically 
relevant POPF after hand-sewn (32.3%) vs. mechanical closure 
(19.8%)(p=0.025) and, in case of splenic preservation, after 
splenic vessel ligation (15/32,46.9%) vs. vascular preservation 
(17/72,23.6%)(p=0.024). Hand-sewn pancreatic remnant 
closure (p=0.023) and splenic vessel ligation in splenic 
preservation (p=0.035) were independent predictive factors for 
the onset of clinically relevant POPF. 
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Conclusion: TachoSil® sponge reinforcement of the proximal 
remnant after distal pancreatectomy reduced neither the rate 
nor the severity of POPF. 
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section pancréatique chez les patients ayant suBi une 
pancréatectomie distaLE pour tumeur. 
This study was approved by the Committee for the Protection of 
Patients under the number CPP 08012, and registered with the 
European Clinical Trials Database EUDRACT under the number 
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Introduction 
While distal pancreatic resections are performed less frequently 
than other pancreatectomies (1), the rate of post-operative 
pancreatic fistula (POPF) is high, ranging from 5% (2) to 64% (3-5), 
according to the definition used (4).   
Several procedures have been proposed to reduce the rate and/or 
severity of POPF after distal pancreatectomy (3): decreasing 
digestive tract secretions (6), main duct ligation (7), various 
techniques of division and/or stump closure (1,5,8-10), different 
types and durations of abdominal drainage (11, 12), and stump 
reinforcement with omentum, absorbable or non-absorbable mesh 
or biological glue (8, 13-18). While some reinforcement materials 
have a mechanical action, reducing the traction on the sutured 
edges, others act by enhanced healing (14). TachoSil®, a sponge 
composed of horse collagen, impregnated with human thrombin 
and fibrinogen, stabilized by albumin, combines enhanced healing 
while exercising a hemostatic role (19) and has been used to 
improve hemostasis and bilistasis on the surface of the divided 
liver (18).  
Several uncontrolled studies seem to indicate that absorbable 
mesh reinforcement could reduce the POPF rate after distal 
pancreatectomy (13,14). One randomized study has shown that 
Seamguard ® or Peristrips Dry ® reinforcement of stapled stump 
closure was effective in decreasing the fistula rate (17). However, 
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to date, only one controlled trial has studied the role of TachoSil® 
for stump closure in distal pancreatectomy (19), concluding that 
TachoSil® did not reduce the overall POPF rate.  
The goal of the present study was to report the results of a French 
multicenter randomized controlled study evaluating the role of the 
TachoSil® sponge in reducing the rate and the severity of 
pancreatic POPF after distal pancreatectomy, separating clinically 
silent from clinically relevant POPF. 
Methods 
Patients 
Patients requiring complete removal of the distal pancreas for 
benign or malignant tumors of the pancreatic body or tail were 
eligible for this randomized controlled trial. Inclusion criteria 
required: life expectancy of at least six months, written informed 
consent before randomization, no history of allergy to human 
thrombin and fibrinogen or collagen, no preoperative signs of 
chronic pancreatitis, and absence of indications for simple 
enucleation or intra-abdominal anastomosis, including 
pancreatoenterostomy (to eliminate fistula related to the 
breakdown of these anastomoses (19)). Patients were randomized 
to receive the sponge, or not, only after the distal pancreas had 
been removed, the stump was closed and the surgeon was sure 
that the TachoSil® sponge could be applied under satisfactory 
conditions.  
Intervention  
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Surgery could be performed either via laparotomy or laparoscopy, 
with or without splenectomy, and in case of splenic preservation, 
with ligature (but preserving the short gastric vessels, as described 
by Warshaw (20)) or not of the splenic vessels. The pancreatic 
stump had to be closed, either manually or stapled, as per 
surgeon’s choice. Selective main pancreatic duct closure (suture) 
was not mandatory but was recommended whenever feasible. The 
TachoSil® sponge was placed on the stump without sutures, 
overlapping the closure line by at least 2.5 cm and held there for at 
least 3 minutes to ensure that it stuck to the stump. Additional 
techniques such as abdominal drainage, omentoplasty and/or 
application of biological glue were left to the appreciation of the 
surgeon.  
Definition of post-operative pancreatic fistula (POPF) 
POPF was defined according to the International Study Group on 
Pancreatic Fistula (ISGPF) (21) as any measurable amount of 
drainage fluid, with amylase concentration greater than 3 times the 
upper limit of normal in the serum on or after post-operative day 3, 
irrespective of its color or aspect, exteriorized through a drain or 
retrieved during reoperation or via percutaneous (sonography or 
CT-guided) aspiration. 
Definition of severity 
This study was double blinded: neither the patients nor the 
independent committee whose role was to evaluate the severity of 
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POPF were aware of the allocations. Patients were categorized 
into two groups of POPF (17, 21, 22): one without any clinical signs 
suggestive of any postoperative complication including patients 
without any signs of POPF and patients with grade A severity (with 
no clinical impact (mainly no prolonged hospital stay)), categorized 
as being “clinically silent”, the other “clinically relevant” (with impact 
on the patient’s hospital course), including Grades B and C 
severity.  
Judgment criteria 
The primary endpoint was the onset of “clinically relevant” POPF. 
The secondary endpoints were: a) the overall POPF rate (ISGPF 
Grades A+B+C), b) interval between operation and the onset of 
POPF, c) median duration of post-operative stay in intensive care 
and/or resuscitative care units and overall hospital stay, d) number 
of post-operative complication(s) (other than POPF), e) adverse 
event(s) i.e. any potentially harmful manifestation related or not to 
the product under investigation, and f) mortality.  
Follow-up 
All patients underwent routine physical examination: daily during 
hospitalization and at three months (± 15 days) after operation, 
date at which the diagnosis of POPF and mortality were definitively 
determined.  
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Adverse events related to TachoSil® 
All adverse events were reported immediately, examined and 
categorized by an independent data safety monitoring board 
(DSMB): the causality (not related, possibly related or probably 
related) was evaluated (23).  
Statistical methods 
Randomization was centralized by a vocal server and stratified 
according to the approach (laparotomy or laparoscopy). The  and 
 risks were fixed at 0.05 and 0.10, respectively, providing 90% 
power (one-sided test). Based on an expected decrease in the 
POPF rate from 30% to 15%, the number of patients necessary to 
satisfy these hypotheses was 262 patients (131 in each group). No 
intermediary analysis was planned. The predictive factors for the 
onset of “clinically relevant” POPF were analyzed by univariate and 
multivariate (step-wise regression) analyses. The log rank test was 
used to compare variables related to durations.  
Results 
Two hundred and ninety-seven patients underwent randomization 
in 45 centers between March 5, 2009 and March 10, 2011. As seen 
in the CONSORT flow chart (24), of these 297 patients, 27 were 
ultimately found to not correctly fulfill the entry requirements, and 
were not included in final analysis (figure 1). 
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Of the 270 patients retained for analysis, 134 were allotted to 
receive the TachoSil® sponge, 136 were the control group. This 
was the intention-to-treat (ITT) population.  
Two patients allotted to TachoSil® did not receive the sponge while 
three patients initially allotted to the control group, actually had the 
TachoSil® sponge, without any diagnostic or operative reason to 
back this choice. Therefore, as concerns the analysis as treated 
(per protocol group), exactly half (135) of the 270 randomized 
patients were assigned to each group. As the discrepancy between 
the two populations represents only 1.9% of the entire population, 
and according to the CONSORT recommendations (24), only the 
ITT analysis (134 vs. 136) is reported hereafter. 
No statistically significant differences were found in patient 
demographics (gender, age or body mass index) (table 1).  
The final pathology reports of the resected specimen showed that 
128/270 patients (47.4 %) had benign disease while 142 (52.6 %) 
had malignant disease (p=0.223). Most cancers were pancreatic 
adenocarcinoma (26.7% of the whole population) (table 2). 
No statistically significant differences were noted between the two 
groups as concerns the duration of operation, the number of 
patients admitted to and duration of patient stay in intensive care 
and/or resuscitation units or overall duration of hospital stay (Table 
3), parenchymal consistency of the pancreatic remnant or the 
technical aspects of the operation (selective closure of the main 
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pancreatic duct, type of division and/or stump closure,  laparoscopy 
or laparotomy, abdominal drainage or not, splenic preservation or 
not and, in case of preservation, ligation or not of the main splenic 
vessels (Table 4). 
POPF 
Of the 270 patients, 150 (55.6%) sustained a POPF (ISGPF 
Grades A, B and C) of which 74 (49.3%) were clinically relevant 
while 76 (50.7%) were clinically silent (27.4% and 28.1%, 
respectively, of the total number of patients) (table 5).  
Comparison of patients with or without TachoSil® 
Clinically relevant POPF 
Forty-one patients (30.6%) had a clinically relevant POPF in the 
TachoSil® group vs. 33 (24.3%) in the control group  (p=0.276) 
(Table 5). The odds ratio (OR) was 1.376 with a 95% confidence 
interval (95%CI) equal to [0.877-2.160]). The hypothesis that 
clinically relevant POPF occurred less often when TachoSil® was 
used, cannot be retained. 
POPF (ISGPF Grades A, B and C) 
No statistically significant difference was noted between patients 
with overall POPF in either group: 73 (54.5%) in the TachoSil® 
group vs. 77 (56.6%) in controls (p=0.807) (Table 5). The OR was 
0.917, (95%CI: [0.613-1.372]). The hypothesis that any grade of 
POPF occurred less often after use of TachoSil® cannot be 
retained. 
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There was no statistically significant difference found between the 
two groups as concerns the interval between operation and the 
onset of clinical POPF (logrank test: p=0.957) or in the 10 patients 
undergoing surgical operation or drainage of an intra-abdominal 
collection after hospitalization: 7 vs. 3, respectively (p=0.217). 
Prognostic factors of POPF 
In univariate analysis, no statistically significant difference was 
found according to whether the POPF occurred in patients with 
benign (34/128) or malignant (40/142) disease (p=0.786). 
The duration of operation was not statistically different in patients 
with or without clinically relevant POPF. Conversely, the duration of 
stay in intensive care and resuscitative care was longer (p=0.003 
and p<0.001, respectively) for patients who sustained a clinically 
relevant POPF. 
No statistically significant differences were noted in the rate of 
clinically relevant POPF according to whether or not: a) the 
pancreatic remnant consistency was normal (vs. chronic 
pancreatitis) (p=0.790); b) the main duct was sutured (p=0.130), c) 
drainage was performed (p=1.0), and in subgroup analysis, 
whether patients underwent splenic preservation or 
splenopancreatectomy (p=0.331). Conversely, there were 
statistically significantly more clinically relevant POPF when 
pancreatic remnant closure was hand-sewn  (32.3%) vs.
mechanical closure (19.8%)(p=0.025) and, in case of splenic 
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preservation,  twice as many clinically relevant POPF when the 
splenic vessels were ligated (15/32, 46.9%) vs. vessel preservation 
(17/72, 23.6%) (p=0.024) (table 6). 
Of the 270 patients, 199 (74.7%) underwent laparotomy while 71 
(26.3%) had a laparoscopic approach. No statistically significant 
difference was noted in the clinically relevant POPF rate between 
laparotomy vs. laparoscopy (30.2% (60/199) vs. 19.7% (14/71): 
(p=0.121). Spleen preservation was performed in 104 patients 
(38.5%), more often via laparoscopy (44/71: 62.0%) than via 
laparotomy (60/199: 30.2%), (p=0.001). When the spleen was 
preserved, 32 patients underwent the Warshaw technique (30.8%), 
11 via laparoscopy vs. 21 via laparotomy, (p=0.322), with no 
statistically significant difference in the clinically relevant POPF rate 
according to route (4/11 via laparoscopy vs. 11/21 via laparotomy 
(p=0.470). 
The variables entered into the multivariate analysis (p<0.10 in 
univariate analysis) included age, method of pancreatic remnant 
closure, splenic preservation (with or without splenic vessel 
ligation), performance of additional procedures or not: only hand-
sewn closure of the pancreatic remnant (p=0.023) and the ligation 
of the splenic vessels after splenic preservation (p=0.035) were 
found to be independent predictive factors for the onset of clinical 
POPF. 
Safety 
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According to the DSMB, 756 adverse events were considered to be 
“not related”, while 85 were considered as “possibly related” to the 
use of TachoSil ®. However, none of these adverse events were 
reported to be related to the onset of any post-operative 
complication. 
Morbidity  
Overall, there were 45 post-operative complications (table 7). 
Nevertheless, there was no statistically significant difference found 
between patients with or without TachoSil® or in patients 
sustaining POPF or not. 
Mortality 
One death occurred in the group randomized to TachoSil®, due to 
acute respiratory distress, while two deaths occurred in the group 
without TachoSil®, one related to shock associated with peritonitis 
and the other due to respiratory failure secondary to pulmonary 
embolism in a patient with infection and unexpected rapidly 
generalized cancer. 
Discussion  
Our results showed that the application of TachoSil® sponge on 
the proximal remnant after distal pancreatectomy reduced neither 
the rate nor the severity of POPF. 
This is the second negative study on the use of TachoSil® in this 
indication (19). As highlighted recently (25,26), it is timely and 
highly relevant to publish well-conducted negative studies in order 
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to avoid publication and reporting bias, more and more prevalent 
today, and a real threat to the validity of decision-making for the 
care of our patients. 
While the primary endpoint and the results were close to those in 
the only previous randomized study on the same topic with the 
same product (19), our study differed in that: a) we showed that 
TachoSil® was ineffective for exclusively clinically relevant POPF 
as well as for all grades of POPF, b) the evaluation of patient 
outcome for both the diagnosis of POPF and the causality of 
adverse events was double blinded, c) the power of making a false 
negative conclusion was twice as strong (our beta error (10%) was 
half that of the Italian study (20%)). Of note, as others (17, 22), our 
trial clearly distinguishes itself from the Italian study (19) in that we 
separated the clinically relevant from the clinically silent grade A 
POPF. Otherwise, the overall POPF (including Grade A+B+C) 
would have been 55.6%, still slightly less than the 65% reported in 
the Italian study (19).  
In multivariable analysis, we found that hand-sewn closure of the 
pancreatic stump and ligation of the splenic vessels in case of 
splenic preservation were statistically significantly associated with 
an increased risk for clinically relevant POPF. This is of interest in 
the modern era where more and more distal pancreatectomies are 
being performed laparoscopically (5, 17): stapled stump closure 
and splenic vessel preservation are the preferred methods in 
laparoscopic distal pancreatectomy. 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
14
At least 18 observational (9), two randomized controlled trials (8, 9) 
and one meta-analysis (3) have compared hand-sewn to some 
other pancreatic stump closure procedure.  
Both the systematic review of observational studies (9) and the 
meta-analysis of Knaebel et al. (3) were in favor of stapled closure. 
This is in agreement with our findings but contrasts with those of 
two high-volume institutional studies (1,5) that found that stapled 
stump closure was associated with a higher POPF rate, perhaps 
because of the crushing injury to the pancreatic parenchyma by the 
jaws of the linear stapler, and one other high-volume study (10) 
that did not find any difference. Likewise, the randomized studies of 
Bassi et al. (8) and Diener et al. (9) both showed a non-statistically 
significant difference in the POPF rate in favor of hand sewn stump 
closure. Of note, in all of these studies (1,3,8,9), the authors did not 
distinguish between clinically silent and clinically relevant POPF, as 
we did in our study.  
Neither splenic preservation nor splenectomy influenced the POPF 
rate in our study. Splenic preservation was found to be a significant 
predictive factor for POPF in two studies (19, 27), but no distinction 
was made according to whether the splenic vessels were 
preserved or not. Conversely, Kleef et al. (1) found a just significant 
higher rate (11.2% vs. 5.1% (p=0.048)) of POPF when 
splenectomy was performed. 
Conversely, our higher rate of POPF after the Warshaw technique 
(20) is in accordance with Adam et al. (28). 
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This contrasts with one case-controlled study (29) and the 
Massachusetts General Hospital series (30), which found that the 
POPF rate did not differ statistically significantly whether 
splenectomy or the Warshaw technique (20) were performed. This 
is also in line with Jain et al., who in a recent systematic review 
(31) was unable to show any statistically significant difference in 
the POPF rate between the Warshaw technique and preservation 
of the splenic vessels (p = 0.15). Here again, however, two of the 
studies (29,30) did not use the same definition of pancreatic fistula 
and, in three studies (29-31), no distinction was made as to the 
severity (21). One possible reason behind our findings could be 
that distinguishing between clinically relevant and clinically silent 
POPF unmasks the potential ischemic effects of splenic vessel 
ligation. 
Our overall POPF rate was 55%, slightly lower that the Italian 
randomized trial (65%)(19), but considerably higher than that 
reported by Diener et al. in the DISPACT trial (9). However, we 
searched for this complication over a three-month period, 
compared to the 7 (30%) and 30 day (36%) analyses in the 
DISPACT trial. Moreover, 15% of their patients had chronic 
pancreatitis or pseudo-cysts, considered to be at low-risk for 
development of POPF.  
One systematic review and meta-analysis (32) found that 
laparoscopic distal pancreatectomy had a statistically significant 
protective effect on the rate of POPF. This contrasts with the 
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results of our study as well as those of Cho et al. (33) who found 
that post-operative complications (including POPF) did not differ 
between laparoscopy and laparotomy. Of note, the meta-analysis 
(32) involved only observational studies and series were quite 
heterogeneous, while the Central Pancreas Consortium study (33) 
involved only expert centers, a potential selection bias.  
Laparoscopy was performed in 71 of 270 patients in our study 
(26%), slightly more than the 20% in the Italian study (19). Splenic 
preservation techniques may be easier to perform laparoscopically: 
almost two thirds of splenic preservation operations (62.0%) were 
performed via laparoscopy in our study, higher than the 48% rate 
reported by Montorsi et al. (19).  Our rate of splenic preservation 
was higher among procedures performed by laparoscopy than by 
an open approach (48% vs. 14%, P < 0.001), possibly in relation to 
the 47.4% proportion of benign disease in our study, and facilitating 
the temptation not to perform splenectomy and to spare splenic 
vessels with the minimally invasive approach (34). Conversely, it is 
possible that mandatory preservation of the short gastric vessels in 
the Warshaw technique (20) might be more difficult to perform 
laparoscopically explaining why 11/32=34.5% were performed via 
laparoscopy vs. 21/32=66% via laparotomy in our study.  
In contrast to the results in our trial, several studies found that 
elective closure of the main pancreatic duct had a protective effect 
(7, 35). However, our study was not powered to determine the role 
of elective main pancreatic duct closure (secondary end-point in 
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our study) on prevention of POPF and to the best of our 
knowledge, there are no randomized controlled trials on this 
technical detail in the literature, only multivariate analyses (7, 35). 
Possible reasons for the discrepancy of results might be the 
variation in technical aspects of duct closure from one institution to 
another, and/or the small number of patients in the studies.  
In spite of the outcomes of two randomized controlled studies 
(11,12), the debate as to the need of post-operative drainage 
(preventive effect on occurrence of clinical POPF or detection of 
POPF vs. its potential deleterious effects) has never been closed. 
Most surgeons in our series (95.6%) left a drain. In our study, there 
was no difference in the rate or severity of POPF whether patients 
had a drain or not. 
Our study confirms that the use of TachoSil is safe, as it was not 
associated with any adverse events. This is in accordance with the 
Italian study (19) as well as a non-interventional multicenter 
prospective, surveillance study (36) in a total of 3098 patients 
recruited at 227 centers in 12 European countries.  
There are several possible weaknesses in our study. First, 45 
centers participated in this multicenter study, possibly explaining 
the relatively high overall fistula rate and the wide range of 
techniques used. However, this is representative of real life 
surgery. Second, our low proportion of malignant disease (53.%) in 
relation to the literature (1, 3, 19) potentially represents a selection 
bias, but this also reflects the multicenter character of our study, 
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and the fact that general hospitals as well as specialized pancreatic 
surgery centers participated in our study. 
Conclusion
While the concept of reinforcing the stump closure with a 
resorbable collagen sponge after distal pancreatectomy appeared 
interesting, our results confirm those from the only other previous 
controlled trial on this topic: the inability of this adjunctive method 
to reduce the rate of POPF, whether overall or, as shown in our 
study only, the rate of clinically relevant POPF. However, it is well 
known that several studies, especially when the results are 
negative, are necessary before strong and methodologically sound  
conclusions can be drawn as to the usefulness or futility of 
therapeutic decisions (37,38). As one controlled randomized trial 
(17) has shown a positive effect of non-absorbable mesh 
reinforcement on the pancreatic stump after distal pancreatectomy, 
further studies are needed with different types of material used for 
reinforcement.  
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